Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

BLUE

Bluebird bio Inc

Apr 26 • 04:00PM ET

0.9228

Dollar change +0.0103
Percentage change 1.13	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM IWN IBB VTWO DFAT IWC ITOT DFAC

Index	RUT	P/E	-	EPS (ttm)	-0.74	Insider Own	1.51%	Shs Outstand	192.74M	Perf Week	-9.53%
Market Cap	177.86M	Forward P/E	-	EPS next Y	-0.88	Insider Trans	-1.31%	Shs Float	189.83M	Perf Month	-32.40%
Income	-91.17M	PEG	-	EPS next Q	-0.44	Inst Own	62.00%	Short Float	17.18%	Perf Quarter	-12.94%
Sales	21.73M	P/S	8.19	EPS this Y	10.88%	Inst Trans	7.50%	Short Ratio	3.90	Perf Half Y	-68.29%
Book/sh	2.08	P/B	0.44	EPS next Y	45.28%	ROA	-16.08%	Short Interest	32.62M	Perf Year	-74.92%
Cash/sh	0.95	P/C	0.97	EPS next 5Y	45.80%	ROE	-47.81%	52W Range	0.88 - 5.53	Perf YTD	-33.13%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-20.06%	52W High	-83.31%	Beta	0.83
Dividend TTM	-	Quick Ratio	1.42	Sales past 5Y	120.04%	Gross Margin	-15.86%	52W Low	4.98%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	1.55	EPS Y/Y TTM	87.79%	Oper. Margin	-1523.91%	RSI (14)	35.57	Volatility	8.70% 8.50%
Employees	-	Debt/Eq	1.36	Sales Y/Y TTM	322.60%	Profit Margin	-419.62%	Recom	2.77	Target Price	3.77
Option/Short	Yes / Yes	LT Debt/Eq	1.04	EPS Q/Q	29.93%	Payout	-	Rel Volume	0.61	Prev Close	0.91
Sales Surprise	-53.53%	EPS Surprise	5.67%	Sales Q/Q	17353.52%	Earnings	Mar 26 BMO	Avg Volume	8.36M	Price	0.92
SMA20	-15.94%	SMA50	-26.45%	SMA200	-62.45%	Trades		Volume	5,138,588	Change	1.13%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-23	Downgrade	HSBC Securities	Hold → Reduce
Dec-08-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$3 → $7
Oct-17-23	Initiated	Cantor Fitzgerald	Neutral
Sep-06-23	Initiated	HSBC Securities	Buy	$4.21
Jul-19-23	Upgrade	BofA Securities	Neutral → Buy	$6 → $10
Jun-01-23	Upgrade	Barclays	Equal Weight → Overweight	$7 → $8
Apr-28-23	Initiated	JP Morgan	Overweight	$7
Mar-07-23	Initiated	Robert W. Baird	Outperform	$10
Aug-05-22	Upgrade	Barclays	Underweight → Equal Weight
Aug-02-22	Upgrade	Raymond James	Mkt Perform → Outperform	$8
Apr-06-22	Downgrade	Cowen	Outperform → Market Perform
Mar-07-22	Downgrade	Barclays	Equal Weight → Underweight	$4
Nov-08-21	Reiterated	Wells Fargo	Equal Weight	$25 → $16
Nov-08-21	Reiterated	Wedbush	Neutral	$22 → $11
Nov-08-21	Reiterated	RBC Capital Mkts	Sector Perform	$26 → $14
Nov-08-21	Reiterated	Canaccord Genuity	Hold	$20 → $15
Nov-08-21	Reiterated	Barclays	Equal Weight	$20 → $13
Nov-08-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$11
Nov-08-21	Downgrade	Goldman	Neutral → Sell	$23 → $10
Aug-10-21	Resumed	William Blair	Mkt Perform

Show Previous Ratings

Apr-26-24 04:43PM	bluebird bio Gets Nasdaq Notice for Late Filing of Annual Report (MT Newswires)
04:05PM	bluebird bio Announces Receipt of Expected Notice from Nasdaq (Business Wire)
Apr-16-24 02:05PM	bluebird (BLUE) Underperforms Industry YTD Amid Challenges (Zacks)
Apr-15-24 08:15AM	Is Bluebird Bio Stock a Buy? (Motley Fool) -6.36%
Apr-13-24 04:22PM	Better Buy: Bluebird Bio Vs. Novavax (Motley Fool)
08:30AM	Loading…
Apr-11-24 08:30AM	Is This Beaten-Down Stock a Good Acquisition Target? (Motley Fool)
08:00AM	bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-02-24 11:33AM	bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 05:20AM	Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst (Motley Fool)
Mar-27-24 11:37AM	bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates (Zacks) +13.75%
10:00AM	Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline (Zacks)
Mar-26-24 07:01AM	bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance (Business Wire) -11.76%
Mar-25-24 04:05PM	bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call (Business Wire)
Mar-19-24 07:44AM	bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up (Zacks)
Mar-18-24 06:05PM	Why Bluebird Bio Stock Flew Higher Than the Market Today (Motley Fool)
08:00AM	Loading…
08:00AM	bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital (Business Wire)
Mar-13-24 07:50AM	Is Bluebird Bio Stock a Buy Now? (Motley Fool)
Mar-11-24 08:00AM	bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy (Business Wire) -7.33%
Mar-05-24 06:56PM	Why Bluebird Bio Stock Dived Into the Red on Tuesday (Motley Fool) -9.15%
Jan-27-24 07:28AM	If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today (Motley Fool)
05:27AM	5 Best 52-Week Low Stocks To Buy Now (Insider Monkey)
Jan-10-24 06:55AM	2 Red Flags for Bluebird Bio Stock (Motley Fool)
Jan-08-24 08:00AM	bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook (Business Wire)
Jan-04-24 03:32PM	Bluebirds Plans to Win in Sickle Cell Come Into Focus (The Wall Street Journal) +5.84%
Jan-03-24 07:15AM	Better Risky Investment: Bluebird Bio vs. Shiba Inu (Motley Fool) -6.80%
Jan-02-24 08:00AM	bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +6.52%
Dec-26-23 08:00AM	Should You Invest in Bluebird Bio Right Now? (Motley Fool)
Dec-24-23 07:39AM	If You Invested $10,000 in Bluebird Bio In 2021, This Is How Much You Would Have Today (Motley Fool)
Dec-23-23 07:30AM	1 Green Flag and 1 Red Flag for Bluebird Bio Stock (Motley Fool)
Dec-22-23 08:45AM	3 Money-Saving Tricks for Investing in Biotech Stocks in 2024 (Motley Fool)
02:23PM	Loading…
Dec-20-23 02:23PM	Bluebird Bio Stock Plunges (Barrons.com) -45.68%
01:54PM	Bluebird Bio Stock Is in Free Fall Weeks After a Landmark FDA Approval. Heres Why. (Barrons.com)
Dec-19-23 09:41PM	bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock (Business Wire) -20.33%
Dec-18-23 04:01PM	bluebird bio, Inc. Announces Proposed Public Offering of Common Stock (Business Wire) -6.73%
Dec-15-23 11:14AM	Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock? (Motley Fool)
Dec-11-23 05:43AM	Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug? (Motley Fool) +7.34%
Dec-10-23 12:02PM	Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels (Business Wire)
Dec-09-23 11:31AM	Long-term Follow-up Data From bluebirds Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events (Business Wire)
Dec-08-23 01:45PM	FDA Approves Worlds First Crispr Gene-Editing Drug for Sickle-Cell Disease (The Wall Street Journal) -40.54%
01:01PM	bluebird bio Details Plans for the Commercial Launch of LYFGENIA Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events (Business Wire)
12:35PM	bluebird bio Announces FDA Approval of LYFGENIA (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events (Business Wire)
Dec-07-23 11:30AM	Bluebird (BLUE) Up 48.2% Since Last Earnings Report: Can It Continue? (Zacks)
08:45AM	These 2 Stocks Could Be About to Soar: Are They Buys? (Motley Fool)
Dec-01-23 07:41AM	bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How (Zacks) +11.52%
Nov-29-23 02:28PM	If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names (InvestorPlace)
Nov-26-23 04:44PM	2 Biotech Stocks That Could Soar in December (Motley Fool)
Nov-24-23 07:00AM	Gene Editing Will Change Medicineand Maybe Health Investing Too (The Wall Street Journal)
Nov-08-23 03:39PM	bluebird bio, Inc. (NASDAQ:BLUE) Q3 2023 Earnings Call Transcript (Insider Monkey) -7.91%
Nov-07-23 05:18PM	Why Bluebird Bio Stock Soared 7% Higher on Tuesday (Motley Fool) +7.27%
08:00AM	Bluebird Bio Inc (BLUE) Reports Q3 2023 Financial Results: Strong Commercial Launch and ... (GuruFocus.com)
07:46AM	Bluebird Bio Q3 Loss Narrows, Tops Estimates; Revenues Miss Estimates (RTT News)
07:27AM	Bluebird: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress (Business Wire)
Nov-04-23 08:45AM	Is Bluebird Bio Stock a Buy? (Motley Fool)
Nov-02-23 09:37AM	bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition (Business Wire)
Oct-30-23 08:00AM	bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million (Business Wire)
Oct-24-23 08:00AM	bluebird bio to Host Third Quarter 2023 Financial Results Conference Call (Business Wire)
Oct-17-23 09:47AM	Dollar Tree upgraded, Microsoft initiated: Wall Street's top analyst calls (The Fly)
Sep-29-23 09:00AM	Where Will Bluebird Bio Be in 1 Year? (Motley Fool)
Sep-20-23 07:21AM	Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio (Motley Fool)
Sep-12-23 07:00AM	More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics (Motley Fool)
05:14AM	2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street (Motley Fool)
Sep-07-23 11:30AM	Bluebird (BLUE) Up 7.3% Since Last Earnings Report: Can It Continue? (Zacks) -7.11%
Sep-05-23 04:05PM	bluebird bio Announces September Investor Events (Business Wire)
Aug-29-23 05:25AM	Is Bluebird Bio a Bargain Buy in September? (Motley Fool)
Aug-28-23 08:30AM	Wall Street Thinks This Tiny Biotech Company Could Soar Soon (Motley Fool)
Aug-24-23 10:15AM	1 Beaten-Down Growth Stock You'd Regret Not Buying on the Dip, According to Wall Street (Motley Fool)
Aug-16-23 07:00AM	bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease (Business Wire)
Aug-08-23 08:25AM	Bluebird Bio (BLUE) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +8.06%
07:18AM	Bluebird: Q2 Earnings Snapshot (AP Finance)
07:00AM	bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress (Business Wire)
07:00AM	2 Magnificent Growth Stocks I'm Buying Hand Over Fist Right Now (Motley Fool)
Aug-05-23 09:40AM	1 Beaten-Down Stock That Could Soar by 89%, According to Wall Street (Motley Fool)
Jul-27-23 11:19AM	Bank of America Says These 2 Stocks Could Double Your Money Heres Why They Could Rally (TipRanks) -5.81%
Jul-25-23 08:00AM	bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update (Business Wire)
Jul-22-23 06:14AM	3 Small-Cap Stocks That Could Be Big-Time Winners (Motley Fool)
Jul-20-23 01:14AM	4 big analyst picks: AMD called a 'Top Pick' at Wolfe; Cisco upped at JPMorgan (Investing.com)
Jul-19-23 12:36PM	Why Bluebird Bio Stock Is Taking Flight Today (Motley Fool) +16.51%
Jun-30-23 10:15AM	Down 51% in 2023, Here's Why Bluebird Bio Stock Could Soon Double, Says Wall Street (Motley Fool)
Jun-29-23 09:53AM	This 1 Problem Could Sink at Least 4 Gene-Editing Stocks (Motley Fool) -5.01%
07:45AM	Is Bluebird Bio Stock a Buy Now? (Motley Fool)
Jun-21-23 07:00AM	bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events (Business Wire)
Jun-15-23 10:00AM	2 Short-Squeeze Candidates That Could Go Parabolic (Motley Fool)
Jun-08-23 11:30AM	Bluebird (BLUE) Down 26% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-01-23 02:09AM	4 big analyst picks: Avis Budget zooms higher on Deutsche upgrade (Investing.com) +5.67%
May-10-23 07:57AM	Will bluebird bio (NASDAQ:BLUE) Spend Its Cash Wisely? (Simply Wall St.)
May-09-23 07:10AM	Bluebird: Q1 Earnings Snapshot (AP Finance) +12.64%
07:00AM	bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress (Business Wire)
Apr-27-23 04:05PM	bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events (Business Wire)
Apr-24-23 03:49PM	With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023 (Benzinga)
07:30AM	bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events (Business Wire)
Apr-13-23 02:17PM	$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis (Benzinga) +17.20%
Apr-06-23 10:15AM	Should Investors Buy the Dip With Bluebird Bio Stock? (Motley Fool)
08:00AM	What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio (Motley Fool)
06:30AM	Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio (Motley Fool)
Apr-02-23 09:15AM	1 Small-Cap Stock That Could Soar in 2023 (Motley Fool)
Mar-30-23 01:54PM	Why Bluebird Bio Stock Is Sinking This Week (Motley Fool)
Mar-29-23 08:15AM	Bluebird Bio (BLUE) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -24.54%
07:00AM	bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress (Business Wire)
Feb-24-23 10:00AM	Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Obenshain Andrew	President and CEO	Mar 04 '24	Sale	1.53	6,095	9,311	279,998	Mar 05 05:40 PM
Klima Thomas J	See Remarks	Mar 04 '24	Sale	1.53	4,573	6,986	124,840	Mar 05 05:39 PM
Colvin Richard A	Chief Medical Officer	Mar 01 '24	Sale	1.53	6,770	10,342	118,368	Mar 05 05:40 PM
Vittiglio Joseph	Chief Business & Legal Officer	Feb 05 '24	Sale	0.90	5,217	4,708	44,783	Feb 06 04:07 PM
Klima Thomas J	See Remarks	Feb 05 '24	Sale	0.90	2,714	2,449	129,413	Feb 06 04:07 PM
Obenshain Andrew	President and CEO	Feb 05 '24	Sale	0.90	1,879	1,696	286,093	Feb 06 04:07 PM
Obenshain Andrew	President and CEO	Jan 05 '24	Sale	1.43	3,162	4,520	287,972	Jan 09 04:05 PM
Colvin Richard A	Chief Medical Officer	Jan 05 '24	Sale	1.42	597	845	125,138	Jan 09 04:05 PM
Krawtschuk Christopher	Chief Financial Officer	Dec 06 '23	Sale	4.52	4,526	20,437	45,474	Dec 08 04:42 PM
Obenshain Andrew	President and CEO	Nov 03 '23	Sale	3.17	807	2,555	291,134	Nov 03 04:10 PM
Colvin Richard A	Chief Medical Officer	Nov 02 '23	Sale	2.98	2,343	6,975	125,735	Nov 03 04:10 PM
Klima Thomas J	See Remarks	Sep 05 '23	Sale	3.79	922	3,493	132,127	Sep 06 04:30 PM
Obenshain Andrew	President and CEO	Aug 10 '23	Sale	3.54	16,929	59,956	291,941	Aug 10 05:00 PM
Klima Thomas J	See Remarks	Jun 02 '23	Sale	3.50	4,130	14,451	133,049	Jun 06 04:06 PM

Open in Screener

EXAS

Exact Sciences Corp.

Apr 26 • 04:00PM ET

58.85

Dollar change +0.06
Percentage change 0.10	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB VXF VBK ARKK ARKG VHT IWR FBT SCHM

Index	-	P/E	-	EPS (ttm)	-1.14	Insider Own	1.04%	Shs Outstand	181.36M	Perf Week	-3.46%
Market Cap	10.68B	Forward P/E	498.48	EPS next Y	0.12	Insider Trans	-5.34%	Shs Float	179.65M	Perf Month	-12.01%
Income	-204.15M	PEG	-	EPS next Q	-0.48	Inst Own	87.66%	Short Float	5.51%	Perf Quarter	-8.45%
Sales	2.50B	P/S	4.27	EPS this Y	19.50%	Inst Trans	-1.74%	Short Ratio	4.01	Perf Half Y	-4.79%
Book/sh	17.34	P/B	3.39	EPS next Y	112.98%	ROA	-3.00%	Short Interest	9.89M	Perf Year	-6.11%
Cash/sh	4.28	P/C	13.74	EPS next 5Y	-	ROE	-6.60%	52W Range	56.05 - 100.77	Perf YTD	-20.45%
Dividend Est.	-	P/FCF	334.58	EPS past 5Y	4.59%	ROI	-3.63%	52W High	-41.60%	Beta	1.26
Dividend TTM	-	Quick Ratio	2.07	Sales past 5Y	43.88%	Gross Margin	70.14%	52W Low	5.00%	ATR (14)	3.08
Dividend Ex-Date	-	Current Ratio	2.32	EPS Y/Y TTM	67.92%	Oper. Margin	-12.20%	RSI (14)	36.06	Volatility	4.04% 4.86%
Employees	6600	Debt/Eq	0.82	Sales Y/Y TTM	19.93%	Profit Margin	-8.17%	Recom	1.32	Target Price	90.59
Option/Short	Yes / Yes	LT Debt/Eq	0.79	EPS Q/Q	61.80%	Payout	-	Rel Volume	0.82	Prev Close	58.79
Sales Surprise	1.26%	EPS Surprise	36.16%	Sales Q/Q	16.98%	Earnings	May 08 AMC	Avg Volume	2.47M	Price	58.85
SMA20	-13.12%	SMA50	-7.10%	SMA200	-16.28%	Trades		Volume	2,018,856	Change	0.10%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-02-24	Upgrade	The Benchmark Company	Hold → Buy	$91
Dec-14-23	Initiated	Guggenheim	Buy	$90
Dec-13-23	Initiated	Wolfe Research	Outperform	$95
Oct-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$90
Sep-28-23	Initiated	Bernstein	Outperform	$83
Aug-02-23	Downgrade	The Benchmark Company	Buy → Hold
May-10-23	Upgrade	Craig Hallum	Hold → Buy	$55 → $85
May-05-23	Initiated	UBS	Neutral	$73
Mar-09-23	Upgrade	Citigroup	Neutral → Buy	$70 → $90
Feb-10-23	Downgrade	Credit Suisse	Outperform → Neutral	$50 → $70
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-19-22	Downgrade	Craig Hallum	Buy → Hold	$60 → $35
Aug-25-22	Initiated	Credit Suisse	Outperform	$55
Jun-03-22	Initiated	Piper Sandler	Neutral	$50
Nov-03-21	Downgrade	Raymond James	Strong Buy → Outperform	$160 → $130
Jul-29-21	Reiterated	Stifel	Buy	$165 → $145
Jul-29-21	Reiterated	Oppenheimer	Outperform	$161 → $155
Jul-29-21	Reiterated	Canaccord Genuity	Buy	$185 → $160
Jul-29-21	Reiterated	BTIG Research	Buy	$155 → $145
Jun-15-21	Initiated	Raymond James	Strong Buy	$160

Show Previous Ratings

Apr-25-24 08:05PM	Analyst Report: Exact Sciences Corporation (Morningstar Research) -7.04%
Apr-24-24 06:15PM	Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
07:16AM	Here's Why Baron Health Care Fund Reduced Exact Sciences Corporation (EXAS) (Insider Monkey)
Apr-22-24 12:44PM	Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings? (Zacks)
11:10AM	10 Best Performing Biotech ETFs in 2024 (Insider Monkey)
06:15PM	Loading…
Apr-17-24 06:15PM	Why Exact Sciences (EXAS) Dipped More Than Broader Market Today (Zacks)
Apr-15-24 06:52AM	Exact Sciences names Aaron Bloomer CFO (MedTech Dive) -8.40%
06:00AM	Exact Sciences Names Aaron Bloomer as New Chief Financial Officer (Business Wire)
Apr-12-24 07:00AM	Here's Why Exact Sciences Corporation (EXAS) Declined in Q1 (Insider Monkey)
06:49AM	Should You Hold ON Semiconductor Corporation (ON)? (Insider Monkey)
06:40AM	Should You be Bullish on the Long-Term Growth of Atlassian Corporation (TEAM)? (Insider Monkey)
Apr-11-24 06:00AM	Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes (Business Wire)
Apr-10-24 06:15PM	Exact Sciences (EXAS) Stock Moves -0.89%: What You Should Know (Zacks)
08:16AM	Search for Cancer Blood Test Continues Despite Illumina-Grail Deals Failure (Barrons.com)
12:00AM	ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy? (TipRanks)
07:37AM	Loading…
Apr-09-24 07:37AM	11 Best Biotech ETFs To Buy (Insider Monkey)
Apr-08-24 12:05PM	Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024 (Business Wire)
07:00AM	Sorry, but Blood Tests Wont Replace Stool Samples or Colonoscopies Yet (The Wall Street Journal)
06:00AM	Exact Sciences Schedules First Quarter 2024 Earnings Call (Business Wire)
Apr-05-24 10:16AM	Freenomes colorectal cancer blood test data underwhelm analysts (MedTech Dive)
Apr-04-24 10:15AM	1 Beaten-Down Cathie Wood Stock to Buy and Hold (Motley Fool)
06:05AM	Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment (Business Wire)
Apr-03-24 09:57AM	Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising (Zacks)
Apr-02-24 04:02PM	Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales (Investor's Business Daily)
Mar-29-24 08:09AM	Exact Sciences, Mayo Clinic share early data on esophageal cancer test (MedTech Dive)
Mar-28-24 06:00AM	Exact Sciences Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer (Business Wire)
Mar-27-24 08:05AM	Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner (Business Wire)
Mar-26-24 07:00AM	3 Growth Stocks to Buy at 52-Week Lows in March (InvestorPlace)
Mar-25-24 09:55AM	How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83% (Zacks)
Mar-22-24 11:30AM	Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue? (Zacks)
08:19AM	Loading…
Mar-18-24 08:19AM	Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM (Zacks)
04:30AM	Guardant posts data for colon cancer blood test amid push from rivals (MedTech Dive)
Mar-14-24 04:16PM	Cathie Wood Darling Exact Sciences, And Rival Guardant Health, Dip On Colon Cancer Updates (Investor's Business Daily)
Mar-13-24 05:03PM	The New England Journal of Medicine Publishes Cologuard Plus Test Results from Pivotal BLUE-C Study (Business Wire)
Mar-11-24 12:59AM	2 Beaten-Down Cathie Wood Stocks With Massive Potential (Motley Fool)
Mar-08-24 09:55AM	Can Exact Sciences (EXAS) Climb 55.43% to Reach the Level Wall Street Analysts Expect? (Zacks)
Mar-07-24 07:59AM	Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer (Business Wire) +9.22%
Mar-04-24 11:52PM	Exact Sciences Corp (EXAS) Director Daniel Levangie Sells 5,000 Shares (GuruFocus.com)
03:49PM	The Top 3 Healthcare Stocks to Buy on Weakness in 2024 (InvestorPlace)
10:38AM	7 Stable Stocks to Buy for 100% Returns by 2025 (InvestorPlace)
Mar-03-24 10:32AM	Hidden Gems: 3 Market Underdogs to Buy at Rock-Bottom Prices (InvestorPlace)
Feb-26-24 06:00AM	Exact Sciences to Participate in March Investor Conference (Business Wire)
Feb-23-24 12:01PM	Analyst Report: Exact Sciences Corporation (Morningstar Research)
Feb-22-24 11:08AM	Exact Sciences Corporation (NASDAQ:EXAS) Q4 2023 Earnings Call Transcript (Insider Monkey) -6.00%
10:30AM	Q4 2023 Exact Sciences Corp Earnings Call (Thomson Reuters StreetEvents)
10:22AM	Exact Sciences (EXAS) Q4 Loss Narrows, Revenues Rise Y/Y (Zacks)
01:30AM	Exact Sciences (EXAS) Q4 2023 Earnings Call Transcript (Motley Fool)
12:06AM	Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight (GuruFocus.com)
Feb-21-24 06:20PM	Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:41PM	Exact Sciences: Q4 Earnings Snapshot (Associated Press Finance)
05:12PM	Exact Sciences Corp Reports Robust Revenue Growth and Positive Free Cash Flow in Q4 2023 (GuruFocus.com)
04:05PM	Exact Sciences Announces Fourth Quarter 2023 Results (Business Wire)
Feb-20-24 02:39AM	LLY, CVS, EXAS: Which Strong-Buy-Rated Healthcare Stock Is the Better Buy? (TipRanks)
Feb-15-24 07:47AM	Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store? (Zacks)
Feb-14-24 10:00AM	Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-13-24 08:12PM	Analyst Report: Exact Sciences Corporation (Morningstar Research)
Feb-10-24 05:06PM	Top 5 CRISPR Stocks To Invest In (Insider Monkey)
Feb-07-24 09:00AM	Cathie Wood Is Selling This Stock: Should You? (Motley Fool) -5.36%
Feb-01-24 06:00AM	Exact Sciences Schedules Fourth Quarter 2023 Earnings Call (Business Wire)
Jan-28-24 09:25AM	3 Stocks to Buy for the Age of Personalized Medicine (InvestorPlace)
Jan-22-24 08:00AM	2 Cathie Wood Growth Stocks to Buy and Hold for the Long Haul (Motley Fool)
Jan-18-24 05:04AM	The Top 3 Stocks in the High-Potential Cancer Testing Market (InvestorPlace)
Jan-13-24 02:05PM	BIIB, ZTS, EXAS: Which Strong Buy Healthcare Stock is Best? (TipRanks)
Jan-08-24 02:48PM	7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024 (InvestorPlace)
Jan-07-24 04:30PM	Exact Sciences Announces Preliminary Fourth Quarter 2023 Results (PR Newswire)
Jan-02-24 06:00AM	Exact Sciences to participate in J.P. Morgan Healthcare Conference (PR Newswire)
Dec-21-23 09:43AM	Exact Sciences' (EXAS) Solid Cologuard Sales, Innovation Aid (Zacks) +6.14%
Dec-20-23 01:49PM	5 Most Promising Gene Editing Stocks According to Hedge Funds (Insider Monkey)
Dec-17-23 05:43AM	1 Supercharged Growth Stock to Buy Before It Soars as Much as 222%, According to Cathie Wood's Ark Invest (Motley Fool)
Dec-14-23 04:02AM	Ark Invest Stock Portfolio: 16 Biggest Positions (Insider Monkey)
Dec-13-23 12:52PM	Here's Why You Should Retain Exact Sciences (EXAS) Stock Now (Zacks)
08:45AM	Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences? (Motley Fool)
Dec-07-23 08:05AM	Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings (PR Newswire)
Dec-05-23 09:11AM	3 Stocks at the Forefront of Personalized Medicine Trend (InvestorPlace)
Dec-04-23 12:13PM	Exact Sciences (EXAS) Up 35.4% YTD: Will the Rally Continue? (Zacks)
Dec-01-23 11:32AM	Why Is Exact Sciences (EXAS) Up 2.5% Since Last Earnings Report? (Zacks)
05:26AM	Exact Sciences Corporation (EXAS) Shares Pulled Back in Q3 (Insider Monkey)
Nov-30-23 04:05PM	Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients (PR Newswire)
Nov-25-23 09:45AM	The 3 Best Digital Health Stocks for Personalized Medicine (InvestorPlace)
Nov-23-23 12:02PM	15 Stocks with Consistent Growth (Insider Monkey)
Nov-20-23 03:06PM	3 Biotech Stocks With Big-Time Breakthrough Potential (InvestorPlace)
09:55AM	Wall Street Analysts See a 51.73% Upside in Exact Sciences (EXAS): Can the Stock Really Move This High? (Zacks)
07:30AM	2 Revolutionary Stocks That Could Turn $1,000 Into $2,000 by 2030 (Motley Fool)
Nov-17-23 08:04PM	Analyst Report: Exact Sciences Corporation (Morningstar Research) +8.39%
07:10AM	Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy (PR Newswire)
Nov-14-23 05:20AM	3 Stocks to Love Despite All of the Wall Street Hate (InvestorPlace) +7.07%
Nov-10-23 07:00AM	7 Biotech Stocks to Buy for Big-Time Gains (InvestorPlace)
Nov-09-23 08:10PM	Analyst Report: Exact Sciences Corporation (Morningstar Research) -5.09%
Nov-06-23 09:35AM	Exact Sciences (EXAS) Just Overtook the 20-Day Moving Average (Zacks)
Nov-03-23 08:09PM	Analyst Report: Exact Sciences Corporation (Morningstar Research) +7.30%
Nov-02-23 07:23PM	Exact Sciences Corporation (NASDAQ:EXAS) Q3 2023 Earnings Call Transcript (Insider Monkey)
04:02PM	Exact Sciences, A Cathie Wood Holding, Comes In Hot With Double-Digit Sales Growth (Investor's Business Daily)
11:03AM	Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises (Zacks)
09:40AM	Q3 2023 Exact Sciences Corp Earnings Call (Thomson Reuters StreetEvents)
01:14AM	The Exact Sciences Corp (EXAS) Company: A Short SWOT Analysis (GuruFocus.com)
12:30AM	Exact Sciences (EXAS) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-01-23 06:06PM	Exact Sciences Corp (EXAS) Reports 20% Revenue Increase in Q3 2023 (GuruFocus.com)
04:05PM	Exact Sciences Announces Third-Quarter 2023 Results (PR Newswire)
06:00AM	Exact Sciences to participate in November investor conferences (PR Newswire)
Oct-31-23 05:20PM	15 Best ARK Stocks To Buy Now (Insider Monkey)

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Baranick Brian	EVP, GM., Precision Oncology	Apr 02 '24	Sale	79.43	924	73,393	13,171	Apr 03 07:30 PM
Condella Sarah	EVP, Human Resources	Apr 01 '24	Sale	70.00	2,000	140,000	71,787	Apr 03 07:30 PM
Condella Sarah	EVP, Human Resources	Mar 28 '24	Sale	70.00	2,000	140,000	73,787	Apr 01 04:30 PM
Conroy Kevin T	President and CEO	Mar 01 '24	Sale	59.32	8,271	490,636	1,299,496	Mar 04 08:38 PM
LEVANGIE DANIEL J	Director	Mar 01 '24	Sale	57.50	5,000	287,500	22,975	Mar 04 08:42 PM
Cunningham Everett	Chief Commercial Officer	Mar 01 '24	Sale	59.32	2,412	143,080	46,179	Mar 04 08:38 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Mar 01 '24	Sale	59.32	2,412	143,080	10,933	Mar 04 08:40 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Mar 01 '24	Sale	59.32	2,323	137,800	14,095	Mar 04 08:36 PM
ORVILLE JACOB A	General Manager, Screening	Mar 01 '24	Sale	59.32	2,154	127,775	14,324	Mar 04 08:42 PM
Doyle James Edward	Director	Mar 01 '24	Sale	57.50	2,000	115,000	50,110	Mar 04 08:39 PM
Condella Sarah	EVP, Human Resources	Mar 01 '24	Sale	59.32	1,724	102,268	75,787	Mar 04 08:37 PM
Herriott James	General Counsel	Mar 01 '24	Sale	59.32	862	51,134	9,125	Mar 04 08:41 PM
Herriott James	General Counsel	Feb 29 '24	Option Exercise	0.00	1,890	0	9,987	Mar 04 08:41 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 29 '24	Option Exercise	0.00	5,291	0	13,345	Mar 04 08:40 PM
Cunningham Everett	Chief Commercial Officer	Feb 29 '24	Option Exercise	0.00	5,291	0	48,591	Mar 04 08:38 PM
Conroy Kevin T	President and CEO	Feb 29 '24	Option Exercise	0.00	18,143	0	1,307,767	Mar 04 08:38 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 29 '24	Option Exercise	0.00	4,724	0	16,418	Mar 04 08:36 PM
Condella Sarah	EVP, Human Resources	Feb 29 '24	Option Exercise	0.00	3,779	0	77,511	Mar 04 08:37 PM
ORVILLE JACOB A	General Manager, Screening	Feb 29 '24	Option Exercise	0.00	4,724	0	16,478	Mar 04 08:42 PM
Conroy Kevin T	President and CEO	Feb 27 '24	Sale	56.89	6,263	356,302	1,289,624	Feb 28 07:35 PM
Cunningham Everett	Chief Commercial Officer	Feb 27 '24	Sale	56.89	3,648	207,535	43,300	Feb 28 07:37 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 27 '24	Sale	56.89	2,710	154,172	8,054	Feb 28 07:36 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 27 '24	Sale	56.89	2,027	115,316	11,694	Feb 28 07:34 PM
Condella Sarah	EVP, Human Resources	Feb 27 '24	Sale	56.89	1,880	106,953	73,732	Feb 28 07:35 PM
ORVILLE JACOB A	General Manager, Screening	Feb 27 '24	Sale	56.89	1,879	106,896	11,754	Feb 28 07:38 PM
Herriott James	General Counsel	Feb 27 '24	Sale	56.89	784	44,602	8,097	Feb 28 07:38 PM
ORVILLE JACOB A	General Manager, Screening	Feb 26 '24	Option Exercise	0.00	3,954	0	13,633	Feb 28 07:38 PM
Cunningham Everett	Chief Commercial Officer	Feb 26 '24	Option Exercise	0.00	7,678	0	46,948	Feb 28 07:37 PM
Herriott James	General Counsel	Feb 26 '24	Option Exercise	0.00	1,648	0	8,881	Feb 28 07:38 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 26 '24	Option Exercise	0.00	5,701	0	10,764	Feb 28 07:36 PM
Condella Sarah	EVP, Human Resources	Feb 26 '24	Option Exercise	0.00	3,954	0	75,612	Feb 28 07:35 PM
Conroy Kevin T	President and CEO	Feb 26 '24	Option Exercise	0.00	13,181	0	1,295,887	Feb 28 07:35 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 26 '24	Option Exercise	0.00	3,954	0	13,721	Feb 28 07:34 PM
Conroy Kevin T	President and CEO	Feb 23 '24	Option Exercise	13.96	102,837	1,435,605	1,344,266	Feb 26 05:00 PM
Condella Sarah	EVP, Human Resources	Feb 23 '24	Sale	59.72	1,021	60,974	71,658	Feb 26 05:00 PM
Conroy Kevin T	President and CEO	Feb 22 '24	Sale	59.78	11,565	691,356	1,241,429	Feb 23 07:59 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 22 '24	Sale	59.78	1,351	80,763	5,063	Feb 23 08:01 PM
Cunningham Everett	Chief Commercial Officer	Feb 22 '24	Sale	59.78	1,350	80,703	39,270	Feb 23 08:00 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 22 '24	Sale	59.78	1,093	65,340	9,767	Feb 23 07:57 PM
ORVILLE JACOB A	General Manager, Screening	Feb 22 '24	Sale	59.78	1,013	60,557	9,679	Feb 23 08:03 PM
Condella Sarah	EVP, Human Resources	Feb 22 '24	Sale	59.78	1,013	60,557	72,679	Feb 23 07:57 PM
COWARD D SCOTT	Director	Feb 22 '24	Sale	59.78	663	39,634	44,493	Feb 23 07:59 PM
Herriott James	General Counsel	Feb 22 '24	Sale	59.78	291	17,396	7,233	Feb 23 08:02 PM
Conroy Kevin T	President and CEO	Feb 21 '24	Sale	61.50	4,975	305,962	1,229,756	Feb 22 07:37 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 21 '24	Sale	61.50	1,493	91,820	3,703	Feb 22 07:38 PM
Condella Sarah	EVP, Human Resources	Feb 21 '24	Sale	61.50	1,079	66,358	71,658	Feb 22 07:36 PM
ORVILLE JACOB A	General Manager, Screening	Feb 21 '24	Sale	61.50	1,078	66,297	8,658	Feb 22 07:40 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 21 '24	Sale	61.50	895	55,042	8,826	Feb 22 07:36 PM
COWARD D SCOTT	Director	Feb 21 '24	Sale	61.50	706	43,419	43,122	Feb 22 07:38 PM
Herriott James	General Counsel	Feb 21 '24	Sale	61.50	415	25,522	6,943	Feb 22 07:39 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 20 '24	Option Exercise	0.00	3,112	0	5,196	Feb 22 07:38 PM
Conroy Kevin T	President and CEO	Feb 20 '24	Option Exercise	0.00	10,374	0	1,234,731	Feb 22 07:37 PM
COWARD D SCOTT	Director	Feb 20 '24	Option Exercise	0.00	2,248	0	43,828	Feb 22 07:38 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 20 '24	Option Exercise	0.00	1,729	0	9,721	Feb 22 07:36 PM
Condella Sarah	EVP, Human Resources	Feb 20 '24	Option Exercise	0.00	2,248	0	72,737	Feb 22 07:36 PM
Herriott James	General Counsel	Feb 20 '24	Option Exercise	0.00	864	0	7,358	Feb 22 07:39 PM
ORVILLE JACOB A	General Manager, Screening	Feb 20 '24	Option Exercise	0.00	2,248	0	9,736	Feb 22 07:40 PM
Conroy Kevin T	President and CEO	Feb 15 '24	Sale	61.43	14,791	908,611	1,224,357	Feb 16 06:22 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 15 '24	Sale	61.43	1,888	115,980	2,084	Feb 16 06:24 PM
COWARD D SCOTT	Director	Feb 15 '24	Sale	61.43	1,376	84,528	41,580	Feb 16 06:23 PM
ORVILLE JACOB A	General Manager, Screening	Feb 15 '24	Sale	61.43	966	59,341	7,488	Feb 16 06:26 PM
Condella Sarah	EVP, Human Resources	Feb 15 '24	Sale	61.43	965	59,280	70,489	Feb 16 06:21 PM
Herriott James	General Counsel	Feb 15 '24	Sale	61.43	421	25,862	6,494	Feb 16 06:25 PM
Conroy Kevin T	President and CEO	Feb 14 '24	Option Exercise	0.00	31,133	0	1,239,148	Feb 16 06:22 PM
Condella Sarah	EVP, Human Resources	Feb 14 '24	Option Exercise	0.00	2,031	0	71,454	Feb 16 06:21 PM
Herriott James	General Counsel	Feb 14 '24	Option Exercise	0.00	883	0	6,915	Feb 16 06:25 PM
ORVILLE JACOB A	General Manager, Screening	Feb 14 '24	Option Exercise	0.00	2,031	0	8,454	Feb 16 06:26 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 14 '24	Option Exercise	0.00	3,972	0	3,972	Feb 16 06:24 PM
COWARD D SCOTT	Director	Feb 14 '24	Option Exercise	0.00	3,972	0	42,956	Feb 16 06:23 PM
Condella Sarah	EVP, Human Resources	Jan 02 '24	Sale	73.50	2,000	147,000	69,423	Jan 04 05:19 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Jan 02 '24	Sale	73.50	879	64,606	7,992	Jan 04 05:17 PM
Condella Sarah	EVP, Human Resources	Dec 14 '23	Sale	70.00	2,000	140,000	71,423	Dec 18 07:49 PM
Cunningham Everett	Chief Commercial Officer	Oct 12 '23	Sale	66.49	13,007	864,835	37,909	Oct 13 07:59 PM
Cunningham Everett	Chief Commercial Officer	Oct 11 '23	Option Exercise	0.00	27,504	0	50,916	Oct 13 07:59 PM
Condella Sarah	EVP, Human Resources	Sep 01 '23	Sale	84.36	4,500	379,620	75,814	Sep 06 04:04 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Aug 21 '23	Sale	82.92	30,210	2,505,013	0	Aug 23 04:08 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Aug 07 '23	Sale	85.04	1,350	114,804	8,871	Aug 08 04:09 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Aug 04 '23	Option Exercise	0.00	2,712	0	10,221	Aug 08 04:09 PM
Doyle James Edward	Director	Jul 27 '23	Sale	97.42	2,000	194,840	52,110	Jul 28 04:06 PM
Herriott James	General Counsel	Jul 19 '23	Sale	100.00	1,300	130,000	5,964	Jul 21 04:04 PM
Zanotti Katherine S	Director	Jun 09 '23	Sale	90.51	3,027	273,974	64,629	Jun 12 04:17 PM
Doyle James Edward	Director	Jun 09 '23	Sale	90.51	1,402	126,895	54,110	Jun 12 04:29 PM
Herriott James	General Counsel	Jun 08 '23	Sale	90.00	1,300	117,000	7,264	Jun 12 04:14 PM
Doyle James Edward	Director	May 26 '23	Sale	80.62	2,000	161,240	51,913	May 31 04:13 PM
Condella Sarah	EVP, Human Resources	May 10 '23	Sale	80.00	6,087	486,960	80,314	May 12 04:11 PM
ORVILLE JACOB A	General Manager, Screening	May 10 '23	Sale	80.00	5,000	400,000	6,423	May 12 04:09 PM
Herriott James	General Counsel	May 10 '23	Sale	79.85	1,300	103,805	8,564	May 12 04:07 PM
Condella Sarah	EVP, Human Resources	May 01 '23	Sale	63.78	1,000	63,780	86,401	May 03 04:04 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

BLUE

Bluebird bio Inc

EXAS

Exact Sciences Corp.

Upgrade your FINVIZ experience